Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-PKD
2025-521276-59-00Phase 3Authorised
- Sponsor
- University of Cologne
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Annual slope of eGFR decline. Planned start Dec 2025; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2025-521276-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521276-59-00.